Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

Primary Central Nervous System Lymphoma

Micronutrients

All Drugs and Chemicals

Anti-Infective Agents

Antineoplastic Agents

Antirheumatic Agents

Dermatologic Agents

Reproductive Control Agents

Hematinics

Vitamins

Leucovorin

Cytarabine

Methotrexate

Rituximab

Vincristine

Procarbazine

Antineoplastic Agents, Immunological

Immunologic Factors

Antimetabolites

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Immunosuppressive Agents

Antiviral Agents

Antidotes

Protective Agents

Trace Elements

Tubulin Modulators

Antimitotic Agents

Folinic Acid

Folate

Vitamin B9

Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine

Antonio Omuro, MD

The purpose of this study is to find out if immunotherapy (rituximab) added to chemotherapy is a safe treatment for primary central nervous system lymphoma (PCNSL). PCNSL is a rare tumor. It is usually treated with chemotherapy and radiation. This combination prolongs survival, but about half of patients relapse. The investigators hope that the addition of rituximab will improve the control of the tumor.

The purpose of this study is to find out if immunotherapy (rituximab) added to chemotherapy is a safe treatment for primary central nervous system lymphoma (PCNSL). PCNSL is a rare tumor. It is usually treated with chemotherapy and radiation. This combination prolongs survival, but about half of patients relapse. We hope that the addition of rituximab will improve the control of your tumor.

The second goal of this study is to assess a lower dose of brain radiation. Brain radiation may cause memory loss or dementia. For patients over the age of 60, the risk of significant memory loss is 80-90%. The risk for younger patients is smaller but less clear. In this, study patients whose tumors are in remission after chemotherapy will be treated with a lower dose of brain radiation. We hope that this lower dose will be less toxic. However, it is also possible that using a lower dose of radiation will be less effective in controlling your tumor.

Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

A Pilot Study of Combined Immunochemotherapy Followed by Reduced Dose RT for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

The toxicity of this combined regimen will be measured using the NCI CTC version 2.0.

Overall Progression Free Survival at 2 years

Northwestern Memorial Hospital

Columbia University

Kentuckiana Cancer Institute

University of Virginia

University of Vermont

Memorial Sloan Kettering Cancer Center

This is a single-armed pilot study designed to evaluate the safety and efficacy of combined immunochemotherapy followed by reduced dose radiation for participants with newly diagnosed PCNSL.

Immunocompetent Pts With Newly Diagnosed Primary CNS Lymphoma

Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine: Immunochemotherapy

Age, Categorical

Age, Continuous

Sex: Female, Male

Dr. Antonio Omuro

Total Number of Participants Who Experienced Acute Treatment Related Adverse Events

Progression Free Survival

Overall Study

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	NCT00594815	Lymphoma	Cytarabine, Leu...	-	Memorial Sloan Kettering Cancer Center
Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	NCT00594815	Lymphoma	Cytarabine, Leu...	-	Memorial Sloan Kettering Cancer Center

Spots Global Cancer Trial Database for cytarabine, leucovorin, methotrexate, procarbazine, rituximab, vincristine